Specifications tableSubject area*Biology*More specific subject area*Inflammation*Type of data*Figures and Tables*How data was acquired*Gene expression profiling using Affymetrix HTA 2.0 Genechip*^*®*^*arrays and scanned using an Affymetrix GeneChip*^*®*^*Scanner 3000*Data format*Raw data CEL files and analyzed data are presented in excel*Experimental factors*PBMCs pretreated with tobacco product preparations*Experimental features*Gene Expression profiles from 20 samples of PBMCs treated with reference tobacco product preparations were analyzed for differential gene expression and select pathway analyses using IPA tool.*Data source location*NCBI database with GEO accession number*[*GSE110027*](ncbi-geo:GSE110027){#intref0010}*(*<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110027>)Data accessibility*Data is with this article*Related research articleArimilli S, Makena P, Liu G, Prasad GL. Distinct gene expression changes in human peripheral blood mononuclear cells treated with different tobacco product preparations. Toxicol In Vitro. *In press*[@bib1]*.***Value of the Data**•This Data in Brief article describes comparative gene expression differences from treatment with combustible and non-combustible tobacco products, which may aid in better understanding of the biological effects of the use of different categories of tobacco products.•The blood-derived gene expression could provide information into the systemic effects of tobacco, and can be useful in conjunction with the lung-derived data to gain more inclusive mechanistic insights into the pathophysiology leading to smoking-related diseases.•The data will be useful to achieve a better understanding of chronic inflammation.

1. Data {#sec1}
=======

The data in the tables describe 1) dose-response values for transcript up- and down-regulation, 2) pair-wise comparisons of smokeless tobacco extract (STE) and Whole Smoke-Conditioned Medium (WS-CM) treatments, and 3) transcript overlapping between medium- and high- WS-CM treatments and STE treatments. The figures illustrate the enriched disease and biological functions by medium- and high-WS-CM, as well as STE. (see [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"})Fig. 1Square map showing the enriched disease and biological functions by medium WS-CM. The Square map was colored based on the z-score, which is a statistical measure of the match between expected relationship direction and observed gene expression. The color scale represents the activation z-score ranging from −1.301 (dark blue) to 1.774 (dark orange). Gray represents a z-score of 0. A z-score \> 2 or \< −2 is considered significant. The actual z-score is weighted by the underlying findings, the relationship bias, and dataset bias.Fig. 1Fig. 2Square map showing the enriched disease and biological functions by high WS-CM. The square map was colored based on the z-score, which is a statistical measure of the match between expected relationship direction and observed gene expression. The color scale represents the activation z-score ranging from −3.244 (dark blue) to 4.902 (dark orange). Gray represents a z-score of 0. A z-score \> 2 or \< −2 is considered significant. The actual z-score is weighted by the underlying findings, the relationship bias, and dataset bias.Fig. 2Fig. 3Square map showing the enriched disease and biological functions by STE. The square map was colored based on the z-score, which is a statistical measure of the match between expected relationship direction and observed gene expression. The color scale represents the activation z-score ranging from −1.785 (dark blue) to 0.212 (dark orange). A z-score \> 2 or \< −2 is considered significant. The actual z-score is weighted by the underlying findings, the relationship bias, and dataset bias.Fig. 3

2. Experimental design, materials, and methods {#sec2}
==============================================

The experimental design is to treat peripheral blood mononuclear cells (PBMCs) with three doses (low, medium and high) of WS-CM, and at a single high dose of STE for 3 hours, which are non-cytotoxic. Isolated RNA was profiled for gene expression by microarray technology. Differentially expressed genes were identified across the three doses of WS-CM relative to untreated control conditions, and with those in STE relative to control conditions. Total number of transcripts differentially regulated by WS-CM in a dose-dependent manner (5829 transcripts upregulated and 3903 downregulated) are presented in [Table S1](#appsec1){ref-type="sec"}. Pairwise comparisons of differentially regulated transcripts (\>2fold) by treatments with different doses of WS-CM and STE are shown in [Table S2](#appsec1){ref-type="sec"}. The overlapping transcripts that were differentially expressed between medium and high doses of WS-CM treatments with STE are summarized in [Tables S3](#appsec1){ref-type="sec"}A and S3B, respectively. Additionally, pathway analyses were performed using IPA software (Qiagen).
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Appendix A. Supplementary data {#appsec1}
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The following is/are the supplementary data to this article:Multimedia component 1Multimedia component 1Multimedia component 2Multimedia component 2Multimedia component 3Multimedia component 3Multimedia component 4Multimedia component 4
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